东软医疗在10个国家设有办事处，向110多个国家的客户进行销售。于2021年，公司的国内和海外销售额分别占其收入的83.2%及16.8%。截至6月30日，公司在全球共安装超过44,000台医学影像设备，其中超过18,000台医学影像设备由超过9,600家国内分销商或中国终端客户购买。截至6月30日，东软医疗安装的超过5,100台医学影像设备已接入到公司的MDaaS平台。The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on September 1, Neusoft Medical Systems Co., Ltd. submitted a listing application to the main board of the Hong Kong Stock Exchange for the third time. CICC and Goldman Sachs are its joint sponsors.
Neusoft Medical was founded in 1998 and is a leading provider of medical imaging solutions and services in China. According to Frost & Sullivan, based on the total number of systems installed in 2021, the company is the largest domestic computed tomography system manufacturer and the fourth largest CT system manufacturer in China, with a market share of 11.5%. Neusoft Medical was one of the first medical imaging equipment companies in China to build an MDaaS platform to address the challenges faced by participants in the Chinese healthcare industry. As of June 30, more than 21,000 customers have used the company's MDaaS solution services, of which more than 8,600 customers have used the company's data storage and other services.
Neusoft Medical has offices in 10 countries and sells to customers in more than 110 countries. In 2021, the company's domestic and overseas sales accounted for 83.2% and 16.8% of its revenue, respectively. As of June 30, the company has installed more than 44,000 medical imaging devices worldwide, of which more than 18,000 medical imaging devices have been purchased by more than 9,600 domestic distributors or Chinese end customers. As of June 30, more than 5,100 medical imaging devices installed by Neusoft Healthcare have been connected to the company's MDaaS platform.
Neusoft Medical provides a variety of medical equipment, products, services, and solutions. The four integrated business segments include: digital medical diagnosis and treatment equipment, medical equipment and medical imaging data services, equipment service and training, and in vitro diagnostic equipment and reagents. The table below shows the company's total revenue by product and service type, absolute amount, and percentage of total revenue for the period indicated.
On the financial side, in 2019, 2020 and 2021, Neusoft Healthcare's revenue was RMB1,908 million, $2,459 million and $2,803 million respectively, while profits were RMB82 million, $93 million and $297 million respectively. For the six months ended June 30, 2021 and 2022, the company's revenue was RMB1,320 million and $1,502 million respectively, and profits were RMB88 million and $219 million respectively.
